{"id":963040,"date":"2026-05-14T13:53:04","date_gmt":"2026-05-14T17:53:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/"},"modified":"2026-05-14T13:53:04","modified_gmt":"2026-05-14T17:53:04","slug":"brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/","title":{"rendered":"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BALA CYNWYD, Pa., May  14, 2026  (GLOBE NEWSWIRE) &#8212; Brodsky &amp; Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=69Okr2v92exu97CmjReTjjr6ouhlCJ-ZUwLjTRS8TqKYHpwRALL37grBqLpasn9O1WdJ__aFSsNNm3DBMiEJzxOj7Ize905WFi0kR366kW5zXXqY_bfiH8BNvImiOLFA\" rel=\"nofollow\" target=\"_blank\">jbrodsky@brodskysmith.com<\/a>) or Marc Ackerman (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sxtAjzsFRNr0fjyB9yjLxF58pK1IoviXFb-qk5LFjtS4yUDgzJYcibO-1JpbYxx0pGdWURh5bwD3hj7uGRne1EznwppfHKozFmcWPmyrFpCVWw1vyvMKqIEoP4v9LlG0\" rel=\"nofollow\" target=\"_blank\">mackerman@brodskysmith.com<\/a>) at 855-576-4847. There is no cost or financial obligation to you.<\/p>\n<p>\n        <strong>KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV)<\/strong>\n      <\/p>\n<p align=\"justify\">Under the terms of the Merger Agreement, KalVista will be acquired by Chiesi Group for $27.00 per share in cash with a total value implied of approximately $1.9bn. The investigation concerns whether the KalVista Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.<\/p>\n<p align=\"justify\">Additional information can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5G0C2HE9v-qnns21cStMR1UjiVzJ2LuByB9niFQ_exI28IMpFVMMt6MUwv9XHEQOP3BAEMZzPI5ehIMRJt4263g2Q6kWWr125sDIixYUtg4qC_RU-LVr8_0GOcydgKpBHEbNUlTUeAzUtfxYkeW2TBS5nmECt2o17ExThwqcAeIj2pvbrgdn3Bbj8s2uimgDZ1hSJKNehLHMpBtMJtkk_kiUtkxmhLXY8o5771hhgP14VhpAFW4Cc1xfjrrzRdN5\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.brodskysmith.com\/cases\/kalvista-pharmaceuticals-inc-nasdaq-kalv\/<\/a>.<\/p>\n<p>\n        <strong>Thermon Group Holdings, Inc. (NYSE \u2013 THR)<\/strong>\n      <\/p>\n<p align=\"justify\">Under the terms of the Merger Agreement, Thermon will be acquired by CECO Environmental Corp. (Nasdaq &#8211; CECO) in a stock and cash transaction valued at approximately $2.2 billion where Thermon shareholders will have the ability to elect to receive, for each share of Thermon common stock they own, one of the following forms of consideration: (i) mixed consideration consisting of $10.00 in cash and 0.6840 shares of CECO common stock, (ii) all-cash consideration of $63.89 per share, or (iii) all-stock consideration of 0.8110 shares of CECO common stock per share. The investigation concerns whether the Thermon Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.<\/p>\n<p align=\"justify\">Additional information can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5G0C2HE9v-qnns21cStMR1UjiVzJ2LuByB9niFQ_exJa8MinkD_QhyPhxjN2Huooi3XxaJPznMWLbd8CyUY3Rwl1kLG5Y-7MTvlM_q3eTMenaSOP30RywPafzGn9GUIqPhUNslsNNjh1dHieml0xNjV4GurWghaEi0DwRC99FHEiYpw4DhCodkFYYTIcziVB4x6muqUTYEvjEkz8QSgew15PS2V4n307CfcKDfBQnWQ=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.brodskysmith.com\/cases\/thermon-group-holdings-inc-nyse-thr\/<\/a>.<\/p>\n<p>\n        <strong>Sila Realty Trust, Inc. (NYSE \u2013 SILA)<\/strong>\n      <\/p>\n<p align=\"justify\">Under the terms of the Merger Agreement, Sila will be acquired by certain affiliates of Blue Owl Capital Inc. (NYSE &#8211; OWL) for $30.38 per share in an all-cash transaction valued at approximately $2.4 billion. The investigation concerns whether the Sila Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.<\/p>\n<p align=\"justify\">Additional information can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5G0C2HE9v-qnns21cStMR1UjiVzJ2LuByB9niFQ_exL8dM9YDYpKZCdJqe7ttder2XVMQPuWaCt9N2l_LTbucF61Ibea4s-IKj7n-NJ3jkGXclvzIrN1mXX3Z3iv2MbCf4QaMOFWYT5Do5hNunkXgAtOa0ICCOJWA20KrDw7aYkgHZLY_vrpyerhoGE88hgRAIhuaRJ0IFKMUvGj85j7RYPH3aMdNJauISDAfdu3joc=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.brodskysmith.com\/cases\/sila-realty-trust-inc-nyse-sila\/<\/a>.<\/p>\n<p>\n        <strong>Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)<\/strong>\n      <\/p>\n<p align=\"justify\">Under the terms of the Merger Agreement, Lisata Therapeutics will be acquired by Kuva Labs, Inc. (\u201cKuva\u201d) for $4.00 per share in cash plus two non-tradeable contingent value rights (CVRs), payable as follows: (1) $1.00 per share, in cash, within 12 months of the date on which rights to certepetide in the Greater China region revert to Lisata from Qilu Pharmaceutical; and (2) $1.00 per share, in cash, upon the filing of an NDA or similar registration document by Kuva for approval to commercialize certepetide in any indication in any jurisdiction. The investigation concerns whether the Lisata Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company\u2019s shareholders.<\/p>\n<p align=\"justify\">Additional information can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5G0C2HE9v-qnns21cStMR1UjiVzJ2LuByB9niFQ_exJ8iSEsVX6qp6OIr2Bd-Ymtfw8QOi9RdhPfL-1Ss__9bumTH7XAHrRtP0Me3j1x7YmEU2FpmTpmHWvbpxl3kOv5tx_R5MlMLPR5eDN--coqOBwelFwTQjXBSHAGpZ7clp47m4h7e33MGAA158_G4oeCd7je62VFfTXNDtld98OfPzNqY5pAhqOv81RfQRqgHzg=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.brodskysmith.com\/cases\/lisata-therapeutics-inc-nasdaq-lsta\/<\/a>.<\/p>\n<p align=\"justify\">Brodsky &amp; Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky &amp; Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2EzNDMyZTYtYTVlYS00OTE3LWJkZTEtOTcyMmRmMTU4OWNkLTExOTk4MzEtMjAyNi0wNS0xNC1lbg==\/tiny\/Brodsky-Smith-LLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) &#8212; Brodsky &amp; Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV) Under the terms of the Merger Agreement, KalVista will be acquired by Chiesi Group for $27.00 per share in cash with a total value implied of approximately $1.9bn. The investigation concerns whether the KalVista Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company. Additional information can be found &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963040","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) &#8212; Brodsky &amp; Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV) Under the terms of the Merger Agreement, KalVista will be acquired by Chiesi Group for $27.00 per share in cash with a total value implied of approximately $1.9bn. The investigation concerns whether the KalVista Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company. Additional information can be found &hellip; Continue reading &quot;BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T17:53:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)\",\"datePublished\":\"2026-05-14T17:53:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/\"},\"wordCount\":587,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/\",\"name\":\"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=\",\"datePublished\":\"2026-05-14T17:53:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/","og_locale":"en_US","og_type":"article","og_title":"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA) - Market Newsdesk","og_description":"BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) &#8212; Brodsky &amp; Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV) Under the terms of the Merger Agreement, KalVista will be acquired by Chiesi Group for $27.00 per share in cash with a total value implied of approximately $1.9bn. The investigation concerns whether the KalVista Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company. Additional information can be found &hellip; Continue reading \"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-14T17:53:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)","datePublished":"2026-05-14T17:53:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/"},"wordCount":587,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/","name":"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=","datePublished":"2026-05-14T17:53:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDY0NiM3NjA0MzcxIzIxODgyNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-kalvista-pharmaceuticals-inc-nasdaq-kalv-thermon-group-holdings-inc-nyse-thr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BRODSKY &amp; SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq \u2013 KALV), Thermon Group Holdings, Inc. (NYSE \u2013 THR), Sila Realty Trust, Inc. (NYSE \u2013 SILA), Lisata Therapeutics, Inc. (Nasdaq \u2013 LSTA)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963040"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963040\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}